Daniel Heng: Treatment free survival is becoming an important endpoint in different mRCC treatments
Daniel Heng, Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre in Calgary, Alberta, posted on X about recent paper by Mehul Gupta et al., titled “Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis” published on European Urology Oncology.
Authors: Mehul Gupta, Connor Wells, Meredith M. Regan, Wanling Xie, Vishal Navani, Renee Maria Saliby, Naveen S. Basappa, Frede Donskov, Takeshi Yuasa, Kosuke Takemura, Christian K. Kollmannsberger, Megan Crumbaker, Aly-Khan A. Lalani, Thomas Powles, Hedyeh Ebrahimi, Rana R. McKay, Jae-Lyun Lee, Ravindran Kanesvaran, Toni K. Choueiri, Daniel Y.C. Heng
“Treatment free survival is becoming an important endpoint when looking at different mRCC treatments. VEGF alone had shortest TFS. Something to be said about treatment breaks.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023